Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Anti-TNF Induced Psoriasiform Lesions
NCT03629379Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ustekinumab in psoriasiform dermatitis, inflammatory bowel disease (IBD), sponsored by UZ Leuven. Started Jan 2019; status: completed.
02
Drugs
ustekinumab
03
Conditions
psoriasiform dermatitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03629379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629379.